Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019)
Lineage Cell Therapeutics (LCTX) posted quarterly Acquisitions of $3.1 million for Q1 2019, up 966.05% quarter-over-quarter from $292387.0 in Q2 2012.
Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019) Analysis & Trends
Lineage Cell Therapeutics' Acquisitions history runs 4 years deep, the most recent figure standing at $3.1 million for Q1 2019.
- In Q1 2019, Acquisitions changed N/A year-over-year to $3.1 million; the TTM figure through Dec 2019 stood at $3.1 million (changed N/A YoY), while the FY2019 annual figure was $3.1 million, changed N/A from the prior year.
- Acquisitions for Q1 2019 stood at $3.1 million, up from $292387.0 in the prior quarter.
- The five-year high for Acquisitions was $3.1 million in Q1 2019, with the low at $3.1 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 3.12 Mn |
| Jun 30, 2012 | 292,387.00 |
| Sep 30, 2011 | 240,942.00 |
| Jun 30, 2011 | -240,942.00 |
| Mar 31, 2011 | 246,850.00 |
| Dec 31, 2010 | 222,766.00 |